Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Inactivation or attenuation; producing viral subunits
Patent
1993-10-28
1996-10-22
Campell, Bruce R.
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Inactivation or attenuation; producing viral subunits
514 44, 536 231, 536 241, 536 245, C12N 706
Patent
active
055676049
ABSTRACT:
A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides are composed of at least about 50% guanosine nucleotides. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.
REFERENCES:
patent: 5176996 (1993-01-01), Hogan et al.
Pharmaceutical Research, vol. 5, No. 9, issued 1988, G. Zon, "Oligonucleotide Analogue as Potential Chemotherapeutic Agents", pp. 539-549.
Biochemie, vol. 67, issued 1985, Miller et al., "Control of Ribonucleic Acid Function by Oligonucleoside Methylphosphonates," pp. 769-776.
Galasso et al., "Antiviral Agents and Viral Diseases of Man," published 1990 by Raven Press, Ltd. (New York), pp. 87-114, see pp. 94-95.
Nucleic Acids Research, vol. 20, No. 2, issued 1992, Zendegui et al, "In Vivo Stability and Kinetics of Absorption and Disposition of 3'-Phosphopropyl Amine Oligonucleotides," pp. 307-314.
Biosis, Abstract No. 94-032,483, issued 1994, Vlassov et al, "The Effect of Modification of Terminal Groups of Oligonucleotides on Their Stability in Mycoplasma Culture," Biopolim. Kletka, vol. 7, No. 5, (Novosibirsk, USSR), pp. 37-41, see abstract.
Nucleic Acids Research, vol. 17, No. 18, issued 1989, Nelson et al., "Bifunctional Oligonucleotide Probes Synthesized Using a Novel CPG Support Are Able to Detect Single Base Pair Mutations," pp. 7187-7194.
Nucleic Acids Research, vol. 17, No. 18, issued 1989, Nelson et al., "A new and Versatile Reagent for Incorporating Multiple Primary Aliphatic Amines Into Synthetic Oligonucleotides," pp. 7179-7186.
B Dropulic et al (1994) Human Gene Therapy 5:927-939.
P A Pizzo et al (1994) Clinical Infections Diseases 19:177-196.
J S Cohen (1992) Trends in Biotechnology 10:87-91.
H Collins (Mar. 6, 1993) Philadelphia Inquirer p. A1.
Sacramento Bee (Feb. 26, 1994) p. A22.
Sacamento Bee (Nov. 29, 1991) p. B5.
Arizona Republic (Nov. 27, 1991) p. A6.
E R Kern (1990) in Antiviral Agents and Viral Diseases of Man, G J Galasso et al, eds, pp. 94-95.
J G Zendegui (1992) Nucleic Acids Research 20:307-314.
V V Vlasov et al (1991) Biopolim Kletka 7:37-41 (Abstract only).
Fennewald Susan
Ojwang Joshua O.
Rando Robert F.
Zendegui Joseph G.
Aronex Pharmaceuticals, Inc.
Campell Bruce R.
McDaniel C. Steven
LandOfFree
Anti-viral guanosine-rich oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-viral guanosine-rich oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-viral guanosine-rich oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2358044